Streptococcus suis polypeptides and polynucleotides encoding same and their use in vaccinal and diagnostic applications

Abstract

The present invention relates to the field of Streptococcus. More specifically, the present invention relates to the identification of polypeptides and polynucleotide sequences encoding the same which are involved in the pathogenic mechanism of S. suis. The present invention also relates to the use of such polypeptides in compositions and methods for the prevention, the treatment and diagnosis of S. suis-associated diseases and infections caused by S. suis.

The invention claimed is: 
     
       1. An isolated polypeptide comprising an amino acid sequence having at least 75% 95% identity to the amino acid sequence set forth in SEQ ID NO: 1 or in of SEQ ID NO: 4, where said polypeptide does not have the amino acid sequence of SEQ ID NO: 10. 
     
     
       2. The isolated polypeptide of  claim 1 , comprising at least one repetitive amino acid sequence consisting of the amino acid sequence Xaa 1  Ser Xaa 3  Xaa 4  Xaa 5  Met Xaa 7  Xaa 8  Xaa 9  Xaa 10  Xaa 11  Xaa 12  Xaa 13  Xaa 14  Xaa 15  Xaa 16  Pro Xaa 18  Xaa 19  Gln Met Xaa 22  Asn Lys Glu Xaa 26  Xaa 27  Xaa 28  Xaa 29  Xaa 30  (SEQ ID NO 9) wherein
 Xaa 1  is Val, Thr or Ile; 
 Xaa 3  is Lys or GIu; 
 Xaa 4  is Lys or GIu; 
 Xaa 5  is Ala or Gln; 
 Xaa 7  is Thr or Pro; 
 Xaa 8  is Gly, Ser or Val; 
 Xaa 9  is Lys, VaI, Ile or Asn; 
 Xaa 10  is GIu or Val; 
 Xaa 11  is Lys or Asn; 
 Xaa 12  is Gly, Glu or Asp; 
 Xaa 13  is Asn or Met; 
 Xaa 14  is Ile, Ala or Val; 
 Xaa 15  is Glu or Val; 
 Xaa 16  is Pro or Thr; 
 Xaa 18  is Glu or Gln; 
 Xaa 19  is Lys or Glu; 
 Xaa 22  is Thr or Ala; 
 Xaa 26  is Lys or Asn; 
 Xaa 27  is Asp or Glu; 
 Xaa 28  is Asn or Lys; 
 Xaa 29  is Ile or Val and 
 Xaa 30  is Glu or Val. 
 
     
     
       3. The isolated polypeptide of  claim 1 , comprising the amino acid sequence as set forth in SEQ ID NO 10. 
     
     
       4. The isolated polypeptide of  claim 1 , comprising an amino acid having at least 85% identity to the amino acid sequence set forth in SEQ ID NO 1 or in SEQ ID NO 4. 
     
     
       5. The isolated polypeptide of  claim 1 , comprising an amino acid sequence having at least 95% identity to the amino acid sequence set forth in SEQ ID NO 1. 
     
     
       6. The isolated polypeptide of  claim 1 , comprising an amino acid sequence having at least 95% identity to the amino acid sequence set forth in SEQ ID NO 4. 
     
     
       7. The isolated polypeptide of  claim 1 , wherein it elicits a protective response to a Streptococcus suis strain challenge when administered to an animal. 
     
     
       8. The isolated polypeptide of  claim 3 , comprising at least one repetitive amino acid sequence consisting of the amino acid sequence Xaa 1  Ser Xaa 3  Xaa 4  Xaa 5  Met Xaa 7  Xaa 8  Xaa 9  Xaa 10  Xaa 11  Xaa 12  Xaa 13  Xaa 14  Xaa 15  Xaa 16  Pro Xaa 18  Xaa 19  Gln Met Xaa 22  Asn Lys Glu Xaa 26  Xaa 27  Xaa 28  Xaa 29  Xaa 30  (SEQ ID NO 9) wherein
 Xaa 1  is Val, Thr or Ile;   Xaa 3  is Lys or GIu;   Xaa 4  is Lys or GIu;   Xaa 5  is Ala or Gln;   Xaa 7  is Thr or Pro;   Xaa 8  is Gly, Ser or Val;   Xaa 9  is Lys, VaI, Ile or Asn;   Xaa 10  is GIu or Val;   Xaa 11  is Lys or Asn;   Xaa 12  is Gly, Glu or Asp;   Xaa 13  is Asn or Met;   Xaa 14  is Ile, Ala or Val;   Xaa 15  is Glu or Val;   Xaa 16  is Pro or Thr;   Xaa 18  is Glu or Gln;   Xaa 19  is Lys or Glu;   Xaa 22  is Thr or Ala;   Xaa 26  is Lys or Asn;   Xaa 27  is Asp or Glu;   Xaa 28  is Asn or Lys;   Xaa 29  is Ile or Val and   Xaa 30  is Glu or Val.   
     
     
       9. The isolated polypeptide of  claim 4 , comprising at least one repetitive amino acid sequence consisting of the amino acid sequence Xaa 1  Ser Xaa 3  Xaa 4  Xaa 5  Met Xaa 7  Xaa 8  Xaa 9  Xaa 10  Xaa 11  Xaa 12  Xaa 13  Xaa 14  Xaa 15  Xaa 16  Pro Xaa 18  Xaa 19  Gln Met Xaa 22  Asn Lys Glu Xaa 26  Xaa 27  Xaa 28  Xaa 29  Xaa 30  (SEQ ID NO 9) wherein
 Xaa 1  is Val, Thr or Ile;   Xaa 3  is Lys or GIu;   Xaa 4  is Lys or GIu;   Xaa 5  is Ala or Gln;   Xaa 7  is Thr or Pro;   Xaa 8  is Gly, Ser or Val;   Xaa 9  is Lys, VaI, Ile or Asn;   Xaa 10  is GIu or Val;   Xaa 11  is Lys or Asn;   Xaa 12  is Gly, Glu or Asp;   Xaa 13  is Asn or Met;   Xaa 14  is Ile, Ala or Val;   Xaa 15  is Glu or Val;   Xaa 16  is Pro or Thr;   Xaa 18  is Glu or Gln;   Xaa 19  is Lys or Glu;   Xaa 22  is Thr or Ala;   Xaa 26  is Lys or Asn;   Xaa 27  is Asp or Glu;   Xaa 28  is Asn or Lys;   Xaa 29  is Ile or Val and   Xaa 30  is Glu or Val.   
     
     
       10. The isolated polypeptide of  claim 5 , comprising at least one repetitive amino acid sequence consisting of the amino acid sequence Xaa 1  Ser Xaa 3  Xaa 4  Xaa 5  Met Xaa 7  Xaa 8  Xaa 9  Xaa 10  Xaa 11  Xaa 12  Xaa 13  Xaa 14  Xaa 15  Xaa 16  Pro Xaa 18  Xaa 19  Gln Met Xaa 22  Asn Lys Glu Xaa 26  Xaa 27  Xaa 28  Xaa 29  Xaa 30  (SEQ ID NO 9) wherein
 Xaa 1  is Val, Thr or Ile;   Xaa 3  is Lys or GIu;   Xaa 4  is Lys or GIu;   Xaa 5  is Ala or Gln;   Xaa 7  is Thr or Pro;   Xaa 8  is Gly, Ser or Val;   Xaa 9  is Lys, VaI, Ile or Asn;   Xaa 10  is GIu or Val;   Xaa 11  is Lys or Asn;   Xaa 12  is Gly, Glu or Asp;   Xaa 13  is Asn or Met;   Xaa 14  is Ile, Ala or Val;   Xaa 15  is Glu or Val;   Xaa 16  is Pro or Thr;   Xaa 18  is Glu or Gln;   Xaa 19  is Lys or Glu;   Xaa 22  is Thr or Ala;   Xaa 26  is Lys or Asn;   Xaa 27  is Asp or Glu;   Xaa 28  is Asn or Lys;   Xaa 29  is Ile or Val and   Xaa 30  is Glu or Val.   
     
     
       11. The isolated polypeptide of  claim 6 , comprising at least one repetitive amino acid sequence consisting of the amino acid sequence Xaa 1  Ser Xaa 3  Xaa 4  Xaa 5  Met Xaa 7  Xaa 8  Xaa 9  Xaa 10  Xaa 11  Xaa 12  Xaa 13  Xaa 14  Xaa 15  Xaa 16  Pro Xaa 18  Xaa 19  Gln Met Xaa 22  Asn Lys Glu Xaa 26  Xaa 27  Xaa 28  Xaa 29  Xaa 30  (SEQ ID NO 9) wherein
 Xaa 1  is Val, Thr or Ile;   Xaa 3  is Lys or GIu;   Xaa 4  is Lys or GIu;   Xaa 5  is Ala or Gln;   Xaa 7  is Thr or Pro;   Xaa 8  is Gly, Ser or Val;   Xaa 9  is Lys, VaI, Ile or Asn;   Xaa 10  is GIu or Val;   Xaa 11  is Lys or Asn;   Xaa 12  is Gly, Glu or Asp;   Xaa 13  is Asn or Met;   Xaa 14  is Ile, Ala or Val;   Xaa 15  is Glu or Val;   Xaa 16  is Pro or Thr;   Xaa 18  is Glu or Gln;   Xaa 19  is Lys or Glu;   Xaa 22  is Thr or Ala;   Xaa 26  is Lys or Asn;   Xaa 27  is Asp or Glu;   Xaa 28  is Asn or Lys;   Xaa 29  is Ile or Val and   Xaa 30  is Glu or Val.   
     
     
       12. The isolated polypeptide of  claim 1 , comprising an amino acid sequence having 100% identity to the amino acid sequence set forth in SEQ ID NO 1. 
     
     
       13. The isolated polypeptide of  claim 1 , comprising an amino acid sequence having 100% identity to the amino acid sequence set forth in of SEQ ID NO 4. 
     
     
       14. An isolated polypeptide, comprising an amino acid sequence having at least 95% identity to the amino acid sequence set forth in of SEQ ID NO 2, where said polypeptide does not have the amino acid sequence of SEQ ID NO: 10. 
     
     
       15. The isolated polypeptide of  claim 14 , comprising an amino acid sequence having 100% identity to the amino acid sequence set forth in of SEQ ID NO 2. 
     
     
       16. An isolated polypeptide, comprising an amino acid sequence having at least 95% identity to the amino acid sequence set forth in of SEQ ID NO 3, where said polypeptide does not have the amino acid sequence of SEQ ID NO: 10. 
     
     
       17. The isolated polypeptide of  claim 16 , comprising an amino acid sequence having 100% identity to the amino acid sequence set forth in of SEQ ID NO 3. 
     
     
       18. A composition comprising an acceptable carrier and at least one of the following elements: a polypeptide as defined in any one of  claims 1 ,  2 ,  3 ,  4 ,  5 ,  6 ,  7 , and  8  to  17  of claim 1. 
     
     
       19. A composition for eliciting an immune response to Streptococcus or treating Streptococcus suis-associated diseases or infection caused by S. suis, comprising an acceptable carrier and at least one of the following elements: a polypeptide as defined in any one of  claims 1 ,  2 ,  3 ,  4 ,  5 ,  6 ,  7 , and  8  to  17  of claim 1. 
     
     
       20. The composition of  claim 19 , further comprising an adjuvant. 
     
     
       21. An isolated polypeptide fragment of the polypeptide of SEQ ID NO: 4, having at least 15 contiguous amino acid residues of the amino acid sequence of SEQ ID NO: 4.  
     
     
       22. The isolated polypeptide fragment of claim 21, having at least 25 contiguous amino acid residues of the amino acid sequence of SEQ ID NO: 4.  
     
     
       23. The isolated polypeptide fragment of claim 21, having at least 35 contiguous amino acid residues of the amino acid sequence of SEQ ID NO: 4.  
     
     
       24. The isolated polypeptide fragment of claim 21, further including a fusion tag at the N-terminal end thereof.  
     
     
       25. The isolated polypeptide fragment of claim 21, further including at the C-terminal end thereof a repetitive sequence consisting of the amino acid sequence of SEQ ID NO: 9.  
     
     
       26. The isolated polypeptide fragment of claim 25, wherein said repetitive sequence is a first repetitive sequence of a plurality of said repetitive sequence.  
     
     
       27. The isolated polypeptide fragment of claim 22, further including at the C-terminal end thereof a repetitive sequence consisting of the amino acid sequence of SEQ ID NO: 9.  
     
     
       28. The isolated polypeptide fragment of claim 27, wherein said repetitive sequence is a first repetitive sequence of a plurality of said repetitive sequence.  
     
     
       29. The isolated polypeptide fragment of claim 23, further including at the C-terminal end thereof a repetitive sequence consisting of the amino acid sequence of SEQ ID NO: 9.  
     
     
       30. The isolated polypeptide fragment of claim 29, wherein said repetitive sequence is a first repetitive sequence of a plurality of said repetitive sequence.